Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0009402 (
colorectal cancer
)
53,228
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Colonic exfoliated epithelial cells in faecal material provide a source of human DNA which has been analysed for the presence of the tumour marker
ras
, in order to detect early tumour cells. The stool samples were subjected to a preliminary sample preparation step followed by centrifugation. DNA was extracted from both the centrifugation pellet and supernatant fractions, as well as from endoscopy washings, using a conventional phenol chloroform extraction method and was then purified on glass milk or spin columns. The purified DNA was amplified using mitochondrial primers and analysed for
ras
mutations using a non-radioactive, allele specific mismatch method. Corresponding tumour DNA was analysed for mutations using the same method. The results show that approximately 50% of the faecal samples analysed exhibited the presence of
ras
mutations which were also observed in the corresponding tumours. A double mutation was detected in one supernatant. Our findings represent an important stage in the development of a diagnostic test for the early detection of
colorectal cancer
.
...
PMID:Detection of c-Ki-ras mutations in faecal samples from sporadic colorectal cancer patients. 789 Feb 40
Most anticancer agents fail to induce clear responses in the treatment of
colorectal cancer
. This can be explained by involvement of overexpression of the membrane glycoprotein, P-gp 170, which is associated with multidrug resistance (MDR), and/or with involvement of
ras
. Fluoropyrimidines are amongst the few options in the chemotherapeutic treatment of colorectal cancers. 5'-Deoxy-5-fluorouridine (dFUrd) needs intracellular activation via 5-fluorouracil into 5-fluoro-2'-deoxyuridine-5'-monophosphate and 5-fluorouridine-5'-triphosphate. In the present study, the cytotoxic activity of dFUrd in vitro and dFUrd combined with daunorubicin (DNR) was assessed with the (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium) bromide assay in cells with increased P-gp 170 expression versus controls. Surprisingly, dFUrd was most active in cells with high P-gp 170 expression, a finding which can not be explained by intracellular metabolic activity only. The results also show that dFUrd improves the DNR uptake in MDR-positive cells, and this is related with increased cytotoxicity of the anthracycline.
...
PMID:5'-Deoxy-5-fluorouridine increases daunorubicin uptake in multidrug-resistant cells and its activity is related with P-gp 170 expression. 790 63
Aberrant crypt foci (ACF) are microscopic lesions which have been postulated to precede the development of adenomatous polyps, the precursors to
colorectal cancer
. APC and
ras
gene mutations have been shown to be important early molecular events in the development of colorectal neoplasms. The objective of this study was to establish the nature and frequency of these two genetic alterations in ACF harvested from human colorectal resection specimens. One hundred and fifty-four ACF comprised of between 1 and 56 crypts were harvested from the grossly normal mucosa of colorectal resection specimens of 28 patients with varying pathological diagnoses. One hundred and twenty-five ACF from 20 colons were screened for the presence of K-ras codon 12 mutations with a polymerase chain reaction/restriction enzyme-based method. The APC gene mutation cluster region was screened in 65 ACF from 20 colons using a polymerase chain reaction/single strand conformation polymorphism technique. Putative mutations were confirmed by direct sequencing. K-ras codon 12 mutations were identified in 13% (16 of 125) of ACF. We also identified APC mutations in 4.6% (3 of 65) of ACF. The results of this study demonstrate that both APC and K-ras mutations occur in ACF. These observations support the role of the ACF as a
colorectal cancer
precursor and provide further insight into the early genetic changes which occur during colorectal tumorigenesis.
...
PMID:Somatic APC and K-ras codon 12 mutations in aberrant crypt foci from human colons. 792 90
Point mutations in the Ki-
ras
gene belong to the genetic key events in tumorigenesis of
colorectal cancer
. The type and number of point mutations were detected in specimens from patients with colorectal carcinomas stages as Dukes B and C using single-stranded conformational polymorphism analysis and sequencing. G-A transitions in codon 12 were exclusively found in Dukes B tumors, G-T transversions mainly in Dukes C, and G-C transversions only in Dukes C tumors. Apparently, the G-T and G-C transversions are associated with metastatic behavior of colorectal carcinomas, while G-A transitions are not. In several samples, multiple point mutations could be detected in codon 12, the frequency of multiple mutations increasing with the stage of the tumor.
...
PMID:Type and number of Ki-ras point mutations relate to stage of human colorectal cancer. 801 53
Very frequent loss of heterozygosity (LOH) on chromosome 3p has been found in human renal cell carcinoma (RCC). In the present study, we examined LOH at the retinoblastoma (RB), mutated in
colorectal cancer
(MCC) and adenomatous polyposis coli (APC) tumour suppressor genes loci, and mutations of the H-, K-, and N-ras oncogenes. We performed these studies using the polymerase chain reaction (PCR) method followed by restriction fragment length polymorphism (RFLP) and single-strand conformation polymorphism (SSCP) analyses. LOH was detected in 2 of 11 (18.2%), and 2 of 14 (14.3%) informative cases at the MCC and APC loci, respectively, and in none of 15 informative cases at the RB locus in 25 RCCs. LOH at the MCC was accompanied by LOH at the APC locus in two RCCs. No mutation was detected in H-, K-, and N-ras genes in 39 RCCs. Thus, alterations of the known tumour suppressor genes and the
ras
oncogenes were infrequent events in RCC. The results suggest that the genetic pathway in the genesis of RCC differs considerably from that of other common human carcinomas.
...
PMID:Analysis of genetic alterations in renal cell carcinoma using the polymerase chain reaction. 781 22
Colorectal cancer
is hypothesized to arise after the accumulation of multiple mutations in critical oncogenes or tumor suppressor genes. The relative timing of each mutation is unknown because the exact number and types of mutations differ between tumors. However, for every mutation except the first, tumor heterogeneity must exist until clonal dominance is reestablished. This principle was applied to mutant APC genes in eight colorectal adenomas. The APC mutations were homogeneously present throughout the adenomas, including those less than 1 cm in size, but absent from the normal polyp stalks. In one adenoma with APC and
c-K-ras
mutations, both mutations were simultaneously present in only a small discrete portion, suggesting that the
c-K-ras
mutation was acquired after the APC mutation. These findings suggest that when mutations in APC occur, they are usually one of the first events in colorectal carcinogenesis or provide such a strong selective advantage that intratumor heterogeneity is seldom observed.
...
PMID:Further evidence that one of the earliest alterations in colorectal carcinogenesis involves APC. 808 37
Genetic and environmental aspects play an important role in the development of
colorectal cancer
. However, the common molecular alteration in both hereditary and sporadic colon cancer is localized in the APC gene. the APC gene maps in the long arm of chromosome 5 and was discovered in patients with familial adenomatous polyposis (FAP). The search for the APC gene led to the identification of restriction fragment length polymorphisms (RFLPs) in FAP patients. Using these RFLPs in relatives of FAP patients it is possible to make the presymptomatic and prenatal diagnosis. The FAP syndrome is an interesting model of carcinogenesis in vivo. Thus the different stages involved in the FAP syndrome which include hyperproliferative epithelium, adenoma, adenocarcinoma and metastases, have allowed the analysis of molecular alterations in oncogenes and tumor suppressor genes. The APC gene alteration if not inherited, occurs as the earliest molecular alteration in the development of
colorectal cancer
whereas structural alterations of the genes myc,
ras
, p53, MCC and DCC are considered to be late events. All these investigations have lead to 1) a better understanding of the ethiology of cancer and 2) early diagnosis of
colorectal cancer
in both the hereditary and sporadic forms of the disease.
...
PMID:[Molecular genetics of colorectal cancer and carcinogenesis]. 813 31
We studied DNA ploidy, point mutation of Ki-
ras
oncogene codon 12, and p21 expression using paraffin embedded materials from 42 cases of
colorectal cancer
. DNA ploidy was measured by the method of Hedley et al. flow cytometrically. Point mutation of Ki-
ras
oncogene was examined by the method of Bos et al. using a dot-blot screening procedure, and p21 expression was examined immunohistochemically. Incidence of aneuploidy, Ki-
ras
point mutation, and p21 expression was 71.4%, 26.2%, 40.5%, respectively. There was a very weak correlation between p21 expression and pathologic findings, but there was no correlation between pathologic findings and DNA ploidy, as well as Ki-
ras
point mutation. Patients who showed aneuploidy tended to have more point mutation of Ki-
ras
oncogene. There was no correlation between p21 expression and Ki-
ras
point mutation, as well as DNA ploidy. Although there was no correlation between Ki-
ras
point mutation and survival, a significant correlation between survival and DNA ploidy, as well as p21 expression was recognized. Patients who had tumors with diploidy or p21 expression tended to have better prognosis.
...
PMID:[Molecular oncological study on DNA ploidy, Ki-ras point mutation, and p21 expression in colorectal cancer]. 819 91
A rapid, simple, and nonradioactive method for diagnosing point mutations of
c-K-ras
oncogenes in gastroenterologic cancers is described. This method involved the selective amplification of DNA fragments from cancer tissues of surgical specimens with specific oligonucleotide primers, followed by digestion with restriction enzymes that recognized artificially created or naturally occurring restriction sites. To detect codon 12 mutations, an artificial Msp I site was created by introducing a single nucleotide mismatch into the 5' mutagenesis primer. Using a similar approach, an Hae III site was created to detect codon 13 mutations. Bal I and MBo II sites were used to detect codon 61 mutations. A total of 61 gastroenterologic cancer cases were studied. Of 35 cases of
colorectal cancer
, 7 showed mutations: 6 at codon 12 and 1 at codon 13. In 1 of 2 cases of cholangiocellular carcinoma, point mutation at codon 12 was found. One case of duodenal cancer showed point mutation at codon 12. No mutations were found in the cases of hepatocellular carcinoma (4), gastric cancer (12), esophageal cancer (3), or pancreatic cancer (2).
...
PMID:Mutation analysis of K-ras oncogenes in gastroenterologic cancers by the amplified created restriction sites method. 824 18
The Ki-
ras
proto-oncogene is converted into an active oncogene by mutations in codon 12, 13, or 61. The incidence of mutations in the Ki-
ras
oncogene in colorectal adenomas and primary colorectal carcinomas has been shown to be 50-75 and 40-65%, respectively. To determine the role activation of the Ki-
ras
oncogene plays in the progression of colorectal carcinoma, we analyzed DNA from 11 nude-mouse xenografts and from 24 metastases of 22 patients with colorectal carcinoma, using the polymerase chain reaction technique and hybridization with labeled mutation-specific oligomers. Eleven of the 24 metastases (46%) carried mutations, 7 in codon 12 and 4 in codon 13, whereas only 1 nude-mouse tumor (9%) harbored a Ki-
ras
codon-12 mutation. Eleven of these 12 mutations in advanced stages of
colorectal cancer
were localized to the second position of either codon 12 or codon 13, whereas a majority of published
ras
mutations in earlier stages are in the first position of codon 12 of the Ki-
ras
oncogene. We conclude that there is a position specificity of Ki-
ras
oncogene mutations in advanced stages of colorectal carcinoma. In general, however, these mutations do not seem to play an important role in the progression of this cancer.
...
PMID:Position specificity of Ki-ras oncogene mutations during the progression of colorectal carcinoma. 842 1
<< Previous
1
2
3
4
5
6
7
8
9
10
Next >>